Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Chinese Patent Office
Farmers Insurance
Cerilliant
Fish and Richardson
UBS
US Department of Justice
Mallinckrodt
Teva
Covington

Generated: February 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022047

« Back to Dashboard

NDA 022047 describes SEROQUEL XR, which is a drug marketed by Astrazeneca and is included in one NDA. It is available from six suppliers. Additional details are available on the SEROQUEL XR profile page.

The generic ingredient in SEROQUEL XR is quetiapine fumarate. There are fifty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the quetiapine fumarate profile page.
Summary for 022047
Tradename:SEROQUEL XR
Applicant:Astrazeneca
Ingredient:quetiapine fumarate
Patents:0
Therapeutic Class:Antipsychotics
Bipolar Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 022047
Medical Subject Heading (MeSH) Categories for 022047
Suppliers and Packaging for NDA: 022047
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047 NDA AstraZeneca Pharmaceuticals LP 0310-0280 N 0310-0280-39
SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047 NDA AstraZeneca Pharmaceuticals LP 0310-0280 N 0310-0280-60

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 50MG BASE
Approval Date:May 17, 2007TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 200MG BASE
Approval Date:May 17, 2007TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 300MG BASE
Approval Date:May 17, 2007TE:ABRLD:Yes

Expired US Patents for NDA 022047

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-001 May 17, 2007 ➤ Sign Up ➤ Sign Up
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-005 Aug 11, 2008 ➤ Sign Up ➤ Sign Up
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-004 May 17, 2007 ➤ Sign Up ➤ Sign Up
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-002 May 17, 2007 ➤ Sign Up ➤ Sign Up
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-003 May 17, 2007 ➤ Sign Up ➤ Sign Up
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-004 May 17, 2007 ➤ Sign Up ➤ Sign Up
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-003 May 17, 2007 ➤ Sign Up ➤ Sign Up
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-002 May 17, 2007 ➤ Sign Up ➤ Sign Up
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-001 May 17, 2007 ➤ Sign Up ➤ Sign Up
Astrazeneca SEROQUEL XR quetiapine fumarate TABLET, EXTENDED RELEASE;ORAL 022047-005 Aug 11, 2008 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Boehringer Ingelheim
Argus Health
Citi
Merck
Fuji
Mallinckrodt
Federal Trade Commission
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot